Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
The Ajuba protein has three highly correlated and tandem LIM domains at the C-terminus. It has not been found that Ajuba's LIM structure has DNA-binding activity and mainly mediates the interaction of various proteins. It has a preLIM domain rich in glycine and proline residues at the N-terminus. There is also a nuclear export domain (NES) in the preLIM domain that allows Ajuba proteins to shuttle back and forth between the nucleus and cytoplasm, while the LIM domain directs nuclear localization.
At present, research on the biological functions of Ajuba is mostly concentrated in mammals. Due to the presence of the NES functional structure, Ajuba can shuttle back and forth between the nucleus and the cytoplasm. In the nucleus, Ajuba protein mainly binds to various transcription factors and regulates the transcriptional activity of these transcription factors. In the cytoplasm, Ajuba generally binds to transmembrane proteins or signaling proteins to mediate a wide range of biological functions including regulation of cell cycle, cell adhesion and ligation, cell migration, cell proliferation and apoptosis, and cell differentiation.
Ajuba Protein Is Involved in Mediating Signaling Pathway Interactions
In P19 cells deficient in Ajuba, Ajuba acts as a nuclear receptor-specific co-repressor, negatively regulating retinoic acid signaling. During zebrafish heart development, Ajuba plays a central role in the regulation of SHF by linking the RA signal to Is1, a key transcriptional factor of cardiac precursor cells, and binding to sl1, which inhibits its transcriptional activity. In mammalian and Drosophila cells, Ajuba LIM/dJub interacts with LATS/Wts and WW45/Sav to inhibit signaling in the Hippo signaling pathway.
Rauskolb et al. found that Ajuba also binds to Warts to form a complex and inhibits the Hippo pathway by linking to cytoskeletal tension. Therefore, Ajuba acts as a negative regulator in the Hippo signaling pathway. The Sun GP and Irvine KD studies found that the Ajuba protein is a conserved link between JNK and Hippo signaling, and JNK increases Yki and YAP activity by promoting binding of the Ajuba family of proteins to Warts and LATS. Therefore, the Ajuba protein links the JNK signal transduction pathway to regulate Hippo signaling. Tanaka et al. found that Ajuba negatively regulates YAP activity through the LATS family in the NF2-Hippo pathway and inhibits proliferation of malignant mesothelioma cells (MM) via Hippo signaling.
Figure 1. Two mechanisms for Ajuba regulation of the Hippo pathway. (Gumbiner, et al. 2014)
Ajuba Is Involved in the Process of Cell Mitosis and Regulates Cell Cycle
Aurora-A kinase is a serine/threonine kinase that plays a key role in cell mitosis and meiotic cell division. Aurora-A kinase is overexpressed in a variety of cancers. Bai et al. found that the PreLIM domain of Ajuba binds to Aurora-A and leads to autophosphorylation of the Aurora-AC-terminal kinase domain. In addition, Ajuba's LIM domain competitively binds to the N-terminus of Aurora-A, thereby inhibiting the interaction between the N-terminus and C-terminus of Aurora-A.
Bai et al. also found that Aurora-A mutants (AurA-K250G and AurA-D294G/Y295G) could not bind to Ajuba. However, such mutants themselves lack the interaction between the N-terminus and the C-terminus, resulting in defects in the formation of the mitotic spindle, which arrests cell mitosis in the G2/M phase. This suggests that K250, D294/Y295 play a key role in the cell cycle progression of the direct interaction between Aurora-A and Ajuba and the Aurora-A complex.
Ajuba Is Involved in Cell Adhesion
Cell adhesion affects cell growth and fate and provides spatial clues to cell polarity within the tissue. The LIM domain protein Ajuba has been found to be present at the cell-cell contact site and can shuttle into the nucleus to participate in cell adhesion and thereby affect cell fate and growth. Studies have found that in primary keratinocytes, Ajuba recruits cadherin-dependent cell adhesion complexes by binding to α-catenin. Ajuba also interacts directly with F-actin. These data reveal that Ajuba acts as a new component in cadherin-mediated cell junctions. It also suggests that Ajuba may act as a bridge between the cadherin adhesion complex and the actin cytoskeleton, thus contributing to the formation or enhancement of cadherin-mediated cell adhesion.
According to the study of cancer cells, cancer cells have a lower adhesion between cell-cell and cell-matrix than normal cells, which is essential for the invasion and metastasis of cancer cells. Ajuba can enhance cell adhesion by combining with cadherin. Therefore, it can inhibit the invasion and metastasis of cancer cells.
Ajuba Is Involved in Cell Migration
Cell migration requires a sheet-like pseudopod that extends at the leading edge to form a binder complex. Both of these processes are regulated by signaling proteins recruited to the new adhesion site. Studies have found that cell migration in Ajuba-deficient mice is inhibited, with no abnormal attachment of extracellular matrix proteins, cell proliferation or integrin activation. Phosphoinositide phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] is an important regulator of the cytoskeletal organization during cell migration. A study found that the LIM protein Ajuba interacts with the active PI(4)P5 kinase (PIPKI) and the major enzymes in the synthetic PI(4,5)P2 to regulate the expression level of intracellular PI(4,5). In vitro, Ajuba significantly activates the enzymatic activity of PIPKI while inhibiting the activity of PIPKII. Therefore, in addition to its effect on Rac activity, Ajuba can also influence cell migration by modulating the synthesis of PI(4,5)P2 and directly activating PIPKI enzymatic activity.
Ajuba Is Involved in Transcriptional Regulation
Snail transcription factors are central to epithelial-mesenchymal transition (EMT) repressors and major regulators during normal embryonic development and tumor metastasis. The study found that the LIM protein Ajuba is a specific secondary repressor that binds to Snail's transcriptional repression and EMT induction. Using a Xenopus neural crest as a model of Snail or Slug-induced EMT in vivo, the researchers found that Ajuba is a specific co-repressor of Snail/Slug and also contributes to neural crest development. Through EMT, epithelial cells acquire higher interstitial phenotypes such as migration and invasion, anti-apoptosis, and ability to degrade extracellular matrices. Ajuba acts as a co-repressor of the transcription factor Snail in EMT transformation, inhibiting EMT transformation. Therefore, Ajuba can be used as a key molecule for EMT treatment in tumor metastasis.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.